In a groundbreaking study conducted by Mohit Khera, MD, MBA, MPH, researchers have revealed significant findings regarding the safety and effectiveness of testosterone replacement therapy (TRT). Dr. Khera, a renowned urology professor at Baylor College of Medicine, shares important insights from the TRAVERSE trial (NCT03518034) during the 24th Annual Fall Scientific Meeting of Sexual Medicine Society of North America in San Diego, California.
Unlike previous studies, the TRAVERSE trial is the largest randomized placebo-controlled trial conducted on men receiving testosterone. With a sample size of 5200 men, the study aimed to determine the potential risks associated with testosterone gel and placebo administration. The headline revelation: no increased risk of cardiovascular events was observed in men receiving testosterone therapy.
Additionally, the TRAVERSE trial delved into several sub-studies, exploring various aspects of men’s health. One notable finding was the significant improvement in libido among men receiving testosterone therapy. However, the study did not find a significant improvement in erectile function.
Excitingly, the TRAVERSE trial is not limited to these initial findings. Dr. Khera highlights that many secondary and tertiary outcomes are yet to be assessed. These forthcoming studies will examine a range of factors, including anemia, bone mineral density, depression, and diabetes.
The significance of this research cannot be overstated. Data from the TRAVERSE trial contribute to the growing body of knowledge surrounding testosterone replacement therapy. As more information emerges, doctors and researchers will gain a deeper understanding of the benefits and potential risks associated with this treatment.
Q: Does testosterone replacement therapy increase the risk of cardiovascular events?
A: No, according to the TRAVERSE trial, there was no increased risk of cardiovascular events in men receiving testosterone therapy.
Q: What improvements were observed in men receiving testosterone therapy?
A: The TRAVERSE trial found a significant improvement in libido among men receiving testosterone therapy. However, there was no significant improvement in erectile function.
Q: Are there upcoming studies related to testosterone replacement therapy?
A: Yes, the TRAVERSE trial will continue to explore various outcomes, including anemia, bone mineral density, depression, and diabetes.
Please note: This article is a summarized interpretation of the original source. For more in-depth information, refer to the complete study conducted by Mohit Khera, MD, MBA, MPH.